Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Vistagen Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of VTGN: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders9386−7
Shares56.5M40.8M−15.6M (−27.7%)
Value$9.13M$4.15M−$4.98M (−54.6%)

New holders (10)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to VTGN in Q4 2022
InstitutionSharesValue% of portfolio
UBS Group AG182,646$18.3K0.00%
Garden State Investment Advisory Services LLC30,000$3.09K0.00%
Personal Capital Advisors Corp27,100$2.79K0.00%
Financial Advocates Investment Management23,097$2.38K0.00%
Echo45 Advisors LLC15,647$1.61K0.00%
Bleakley Financial Group, LLC14,552$1.50K0.00%
State Board of Administration of Florida Retirement System11,610$1.20K0.00%
AQR Capital Management LLC10,392$1.07K0.00%
Belvedere Trading LLC4,961$5110.00%
Ellevest, Inc.321$330.00%

Sold out (17)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.